A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
Clinical Trial Grant
Awarded By
Eidos Therapeutics
Start Date
May 14, 2025
End Date
April 30, 2032
Awarded By
Eidos Therapeutics
Start Date
May 14, 2025
End Date
April 30, 2032